<DOC>
	<DOCNO>NCT01671332</DOCNO>
	<brief_summary>The overall purpose study determine whether inclusion suramin standard treatment docetaxel improve progression-free survival patient advance non-small cell lung cancer second third line setting .</brief_summary>
	<brief_title>Docetaxel +/- Suramin 2nd Line Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>The overall purpose study determine whether inclusion suramin standard treatment docetaxel improve progression-free survival patient advance non-small cell lung cancer second third line setting . Secondary objective include : - To compare response rate patient treatment arm - To compare overall survival patient treatment arm - To compare toxicity treatment arm - To determine whether survival benefit suramin associate reduce M-phase entry peripheral blood lymphocyte</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Suramin</mesh_term>
	<criteria>Pathologically proven diagnosis nonsmall cell lung cancer Documented disease progression firstline chemotherapy nonsmall cell lung cancer Stable treat CNS metastasis allow Radiation must complete least 2 week prior start protocol treatment Major surgery must complete least 4 week prior start protocol treatment ECOG performance status 02 Sexually active patient must use adequate contraception Adequate bone marrow function Adequate renal function Adequate liver function Severe hypersensitivity reaction docetaxel Preexisting grade 3 4 neuropathy Women pregnant breastfeeding Uncontrolled intercurrent illness Receipt 3 prior chemotherapy regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Carcinoma , non small cell lung</keyword>
	<keyword>Second line</keyword>
	<keyword>Third line</keyword>
</DOC>